Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma


RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV solid tumors, lymphoma, or myeloma.

Full Title of Study: “Phase I Evaluation of Interferon-alpha-1b in Solid Tumors, Lymphoma or Myeloma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2004

Detailed Description

OBJECTIVES: – Confirm tolerance and safety of interferon alfa-1b (IFN-α1b) in patients with stage IV solid tumors, lymphoma, or myeloma. – Determine the maximum tolerated dose (MTD) of IFN-α1b given daily by subcutaneous injection in these patients. OUTLINE: This is a dose-escalation study. Patients receive interferon alfa-1b subcutaneously once daily for at least 1 month. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of interferon alfa-1b until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


  • Biological: recombinant interferon alpha-1b
    • interferon
  • Drug: IFN
    • IFN daily

Arms, Groups and Cohorts

  • Experimental: Treatment
    • IFN weekly

Clinical Trial Outcome Measures

Primary Measures

  • Tolerance and safety as measured by any ≥ Grade IV granulocyte toxicity or any Grade III toxicity thought to be drug related at 1 week after each course
    • Time Frame: 3 years

Participating in This Clinical Trial


  • Histologically confirmed malignancy, including, but not limited to, renal cell carcinoma, melanoma, Kaposi's sarcoma, breast carcinoma, lymphoma, myeloma, or tumors of endothelial origin – Stage IV disease – Refractory to standard therapy – Measurable or evaluable disease – Evaluable disease can include clinically or radiographically nonmeasurable tumor or specific tumor markers – Patients with prior solitary CNS metastasis allowed – Must have had prior definitive therapy ≥ 3 months previously – No requirement for glucocorticoids unless for physiologic replacement – No multiple CNS metastases PATIENT CHARACTERISTICS: – ECOG performance status 0-1 – Granulocyte count ≥ 1,500/mm³ – Platelet count ≥ 100,000/mm³ – Creatinine ≤ 1.3 times upper limit of normal (ULN) OR – Creatinine clearance of 60 mL/min – Bilirubin ≤ 1.3 times ULN – AST ≤ 5 times ULN – No pregnant or lactating women – Fertile women and men, unless surgically sterile, must use effective contraception – No history of serious cardiac arrhythmia or cardiac arrhythmia requiring treatment – No congestive heart failure – No angina pectoris – No New York Heart Association class III or IV disease – No other severe cardiovascular disease – No known seizure disorder – No known HIV or hepatitis B surface antigen positivity – No active clinical infection requiring antibiotics within the past 7 days PRIOR CONCURRENT THERAPY: – See Disease Characteristics – At least 4 months since prior interferon therapy and/or ≤ 400 million units of interferon – At least 3 weeks since prior major surgery requiring general anesthesia – At least 3 weeks since prior radiotherapy or chemotherapy – Treatment with hormones or other chemotherapeutic agents may not be administered except for steroids given for preexisting adrenal failure or hormones administered for nondisease-related conditions (e.g., insulin for diabetes) – No prior organ allograft – No concurrent dexamethasone, other steroidal antiemetics, or anti-inflammatories – No concurrent palliative radiotherapy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 120 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Cleveland Clinic
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ernest C. Borden, MD, Study Chair, The Cleveland Clinic

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.